Bismuth subsalicylate (Bismol) has got antisecretory, anti-inflammatory, and anti-diarrheal properties. It is used to treat the following conditions:
-
For the symptomatic treatment of diarrhea.
-
For the treatment of indigestion, relief of gas, heartburn, upset stomach, and nausea.
-
As a part of combination therapy for the eradication of H.pylori infection.
-
For the treatment and prophylaxis of travelers diarrhea.
Bismuth subsalicylate Dose in Adults
Dose in the treatment of Dyspepsia and Diarrhea:
- 524 mg orally every half to one hour or 1,050 mg every one hour as needed for up to 2 days
- The maximum dose should not exceed 4,200 mg per day [8 doses (regular strength); 4 doses (maximum strength)]
Dose in the prophylaxis of Traveler's diarrhea ( off-label use):
- 524 mg orally four times a day with meals and at bedtime.
- Safety beyond 3 weeks has not been established.
Dose in the treatment of Traveler's diarrhea (as off-label use):
- 524 mg orally every half to one hour as needed up to 8 doses/24 hours
Off label use as a part of a combination regimen for the eradication of Helicobacter pylori infection:
- Bismuth quadruple therapy:
- 300 mg orally four times a day (in combination with tetracycline 500 mg four times a day, either metronidazole 500 mg 3 or 4 times a day, and standard-dose proton pump inhibitor two times a day) for 10 - 14 days.
Bismuth subsalicylate Dose in Childrens
Note: Patients allergic to aspirin should avoid bismuth subsalicylate. Furthermore, it should not be used during a viral illness such as chickenpox or flu due to the risk of Reye syndrome.
Dose in the treatment of Diarrhea:
- Children 3 - 12 years:
- Regular strength:
- 3 - 6 years:
- 87 mg orally every half to one hour as needed.
- 6 - 9 years:
- 175 mg orally every half to one hour as needed.
- 9 - 12 years:
- 262 mg orally every half to one hour as needed
- Note: Do not exceed 8 doses/day
- 3 - 6 years:
- Regular strength:
- Children older than 12 years and Adolescents:
- Regular strength:
- 524 mg orally every half to one hour as needed.
- Maximum strength:
- 1,050 mg orally every hour as needed
- The total dose should not exceed 8 doses per day (regular strength) or four doses per day (maximum strength)
- Regular strength:
Dose in the treatment of Dyspepsia:
- Children older than 12 years and Adolescents:
- Regular strength:
- 524 mg orally every half to one hour as needed.
- Maximum strength:
- 1,050 mg orally every hour as needed
- The total dose should not exceed 8 doses per day (regular strength) or four doses per day (maximum strength)
- Regular strength:
Dose in the treatment of chronic Diarrhea:
- Infants older than 2 months:
- 44 mg orally every 4 - 6 hours
- Children less than 2 years:
- 44 mg orally every 4 hours or 87 mg four times a day.
- Children 2 to 3 years of age:
- 87 mg orally every 4 - 6 hours
- Children 3 to 4 years of age:
- 87 mg orally every four hours
- Children 4 - 6 years:
- 175 mg orally every four hours
Bismuth Subcalicylate dose in the treatment of Helicobacter pylori-associated antral gastritis (as part of combination therapy):
- Children and Adolescents:
- 8 mg/kg/day orally in two divided doses for 10 - 14 days.
- The dose may be administered four times a day.
Pregnancy Risk Factor: C
- The drug's salicylates component crosses the placental boundary.
- It should not be used for acute diarrhea during pregnancy.
- It is also not recommended for the prevention or treatment of traveler's diarrhea.
Use of bismuth subsalicylates during breastfeeding
- Breastmilk is a source of the drug's salicylate component. Case reports have reported adverse reactions.
- Avoid it while breastfeeding.
- It is not recommended to treat or prevent traveler's diarrhoea while breastfeeding
Bismuth subsalicylate Dose in Renal Disease:
- Adjustment in the dose has not been recommended in patients with renal disease.
Bismuth subsalicylate Dose in Liver Disease:
- Adjustment in the dose has not been recommended in patients with liver disease.
Side Effects Frequency not defined
- Central Nervous System:
- Anxiety
- Confusion
- Depression
- Headache
- Slurred Speech
- Gastrointestinal:
- Grayish black fecal Discoloration
- Tongue Discoloration
- Neuromuscular & Skeletal:
- Muscle Spasm
- Weakness
- Otic:
- Hearing Loss
- Tinnitus
Contraindication to Bismuth subsalicylate include:
- Patients allergic to salicylates or those who take other salicylates should not use it.
- Patients suffering from peptic ulcer disease
- Melena and black tarry stool are signs of gastrointestinal bleeding.
Warnings and Precautions
- Neurotoxicity:
- Neurotoxic effects may occur if you take large amounts. Patients with neurological diseases should be cautious.
Bismuth subsalicylate: Drug Interaction
|
Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.) |
May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. |
|
Ajmaline |
Salicylates may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. |
|
Ammonium Chloride |
May increase the serum concentration of Salicylates. |
|
Angiotensin-Converting Enzyme Inhibitors |
Salicylates may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors. |
|
Anticoagulants |
Salicylates may enhance the anticoagulant effect of Anticoagulants. |
|
Benzbromarone |
Salicylates may diminish the therapeutic effect of Benzbromarone. |
|
Blood Glucose Lowering Agents |
Salicylates may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. |
|
Corticosteroids (Systemic) |
|
|
Loop Diuretics |
Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates. |
|
Potassium Phosphate |
May increase the serum concentration of Salicylates. |
|
Probenecid |
Salicylates may diminish the therapeutic effect of Probenecid. |
|
Salicylates |
May enhance the anticoagulant effect of other Salicylates. |
|
Thrombolytic Agents |
Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur. |
|
Valproate Products |
Salicylates may increase the serum concentration of Valproate Products. |
|
Risk Factor D (Consider therapy modification) |
|
|
Carbonic Anhydrase Inhibitors |
Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated. If another combination is used, monitor patients closely for adverse effects. Tachypnea, anorexia, lethargy, and coma have been reported. Exceptions: Brinzolamide; Dorzolamide. |
|
Ginkgo Biloba |
|
|
Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry) |
May enhance the adverse/toxic effect of Salicylates. Bleeding may occur. |
|
Hyaluronidase |
Salicylates may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. |
|
Methotrexate |
Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern. |
|
Nonsteroidal Anti-Inflammatory Agents (Nonselective) |
May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal AntiInflammatory Agents (Nonselective). |
|
PRALAtrexate |
Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern. |
|
Tetracyclines |
Bismuth Subsalicylate may decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable. Exceptions: Eravacycline. |
|
Varicella Virus-Containing Vaccines |
Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop. |
|
Vitamin K Antagonists (eg, warfarin) |
Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists. |
|
Risk Factor X (Avoid combination) |
|
|
Bismuth Subcitrate |
Bismuth-Containing Compounds may enhance the neurotoxic effect of Bismuth Subcitrate. |
|
Dexketoprofen |
Salicylates may enhance the adverse/toxic effect of Dexketoprofen. Dexketoprofen may diminish the therapeutic effect of Salicylates. Salicylates may decrease the serum concentration of Dexketoprofen. Management: The use of high-dose salicylates (3 g/dayor more in adults) together with dexketoprofen is inadvisable. Consider administering dexketoprofen 30-120 min after or at least 8 hrs before cardioprotective doses of aspirin to minimize any possible interaction. |
|
Influenza Virus Vaccine (Live/Attenuated) |
May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop. |
|
Sulfinpyrazone |
Salicylates may decrease the serum concentration of Sulfinpyrazone. |
How to take Bismuth subsalicylate?
- The oral formulation should be shaken well before its use.
- The chewable tablets should be chewed thoroughly and allowed to dissolve in the mouth before swallowing.
- The non-chewable tablets should be swallowed with a full glass of water.
Mechanism of action of Bismuth subsalicylate:
- It is antimicrobial, antisecretory and has some anti-inflammatory properties.
- Bismuth is antimicrobial and can be used to fight both bacterial pathogens and viruses.
- The salicylate component has antisecretory properties.
Bismuth is less than 1%absorbedHowever, over 80% of subsalicylate components are absorbed. More than 90% is absorbed.
Proteins bound. It isMetabolizedIn the gastrointestinal tract, and converted into bismuth or salicylic acid in there.
The terminalHalf-life eliminationThe time it takes to make bismuth from bismuth is between 21 and 72 days, while the time it takes to make salicylate is between 2 and 5 hours.
The urine excretes the salicylate, while the urine excretes the bismuth.
International Brands of Bismuth subsalicylate:
- Bismatrol Maximum Strength
- Bismatrol
- Diotame
- Geri-Pectate
- Kao-Tin
- Peptic Relief
- Pepto-Bismol InstaCool
- Pepto-Bismol
- Pink Bismuth
- Stomach Relief Max St
- Stomach Relief
- Bisbacter
- Bismucar
- Bismutol
- Bitni X Forte Suspension
- Facidmol
- Gastro-Bismol
- Gastro-Bismol L
- Kalbeten
- Peptolite
- Pink Bismuth
- Stobiol
Bismuth subsalicylate brands in Pakistan:
|
Bismuth Subsalicylates [Susp 88 mg/5ml] |
|
| Akso-D | Akson Pharmaceuticals (Pvt) Ltd. |
| Bismol | Macter International (Pvt) Ltd. |
|
Bismuth Subsalicylates [Tabs 265 mg] |
|
| Akso-D | Akson Pharmaceuticals (Pvt) Ltd. |
| Bismol | Macter International (Pvt) Ltd. |